<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670525</url>
  </required_header>
  <id_info>
    <org_study_id>15-384</org_study_id>
    <nct_id>NCT02670525</nct_id>
  </id_info>
  <brief_title>Matched Targeted Therapy For High-Risk Leukemias</brief_title>
  <official_title>Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is seeking to gain new knowledge about Recurrent, Refractory, or High
      Risk Leukemias in children and young adults.

      This study is evaluating the use of specialized testing called leukemia profiling. Once the
      profiling is performed, the results are evaluated by an expert panel of physicians,
      scientists and pharmacists. This may result in a recommendation for a specific cancer therapy
      or a clinical trial called matched targeted therapy (MTT). The results of the leukemia
      profiling and, if applicable, the MTT recommendation will be communicated to the
      participant's primary oncologist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine whether it is possible to use profiling results and determine a
      matched targeted therapy for patients with leukemia. It will describe the range of mutations
      found in patients with leukemia with this type of profiling, and describe the clinical
      outcomes of patients who receive a matched targeted therapy.

      Our tissues and organs are made up of cells. Cancer occurs when the molecules that normally
      control cell growth are damaged. The damage results in unchecked cell growth which causes a
      tumor, a collection of cancer cells. The damage is referred to as an alteration. There are
      different types of cancer-causing alterations. Genes are the part of cells that contain the
      instructions which tell our cells how to make the right proteins to grow and work. Genes are
      composed of DNA letters that spell out these instructions.

      By participating in this study, the participant's leukemia cells will be tested for cancer
      causing alterations. This testing is called leukemia profiling. The leukemia profiling will
      be performed using bone marrow or blood that has already been obtained during a clinical
      test. Alternately, the profiling may be done on leukemia cells that are planned to be
      obtained as part of routine clinical care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with actionable alterations</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Somatic genomic alterations</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Results Reporting</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Recurrent, Refractory, or High Risk Leukemias</condition>
  <condition>Matched Targeted Therapy</condition>
  <arm_group>
    <arm_group_label>Relapsed/Refractory leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Relapsed/refractory leukemia
Acute lymphoblastic leukemia, first or greater relapse
Acute myeloid leukemia, first or greater relapse
Leukemia refractory to induction chemotherapy
Other recurrent leukemia
After the screening procedures confirms patient eligibility:
Leukemia Profiling will be performed
Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New diagnosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: New diagnosis
Acute myeloid leukemia, new diagnosis (excluding acute promyelocytic leukemia (APL))
New diagnosis infant MLL-rearranged ALL or low hypodiploid (&lt;40 chromosomes) ALL
Rare leukemia- e.g., JMML, leukemia of ambiguous lineage
Secondary leukemia
After the screening procedures confirms eligibility:
Leukemia Profiling will be performed
Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Leukemia Profiling</intervention_name>
    <description>Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.</description>
    <arm_group_label>Relapsed/Refractory leukemia</arm_group_label>
    <arm_group_label>New diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth to â‰¤ 30 years at study entry

          -  Diagnosis: Patients will be enrolled in one of the two cohorts based on diagnosis:

        Cohort 1: Relapsed/refractory leukemia

          -  Acute lymphoblastic leukemia, first or greater relapse

          -  Acute myeloid leukemia, first or greater relapse

          -  Leukemia refractory to induction chemotherapy

          -  Other recurrent leukemia

        Cohort 2: New diagnosis

          -  Acute myeloid leukemia, new diagnosis

          -  New diagnosis infant MLL-rearranged ALL or low hypodiploid (&lt;40 chromosomes) ALL

          -  Rare leukemia- e.g., JMML, leukemia of ambiguous lineage

          -  Secondary leukemia

        Pathologic Criteria

          -  Histologic confirmation of leukemia at the time of diagnosis or recurrence

        Specimen Samples

          -  Sufficient leukemia specimen available for profiling from diagnosis or recurrence OR
             bone marrow aspirate/blood draw/pheresis/other fresh sample of patient leukemia cells
             planned for clinical care anticipated to allow collection of minimum specimen for
             testing.

        Exclusion Criteria:

          -  Insufficient leukemia specimen available for profiling from diagnosis or recurrence;
             or bone marrow evaluation/blood draw/other leukemia cell sample NOT planned to be
             obtained for clinical care; or peripheral blast percentage &lt;20% AND clinical blood
             draw not planned.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yana Pikman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yana Pikman, MD</last_name>
    <phone>617-632-4754</phone>
    <email>YPIKMAN@PARTNERS.ORG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Place, MD, PhD</last_name>
    <phone>617-632-2313</phone>
    <email>andrew_place@dfci.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mignon Loh, MD</last_name>
      <phone>415-514-0853</phone>
      <email>Lohm@peds.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Mignon Loh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Maloney, MD</last_name>
      <phone>720-777-6740</phone>
      <email>Kelly.Maloney@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Maloney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Brown, MD</last_name>
      <phone>410-955-8817</phone>
      <email>Pbrown2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Pikman, MD</last_name>
      <phone>617-632-4754</phone>
      <email>YPIKMAN@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Yana Pikman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lewis B Silverman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Place, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital's and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Gossai, MD</last_name>
      <phone>612-813-5940</phone>
      <email>Nathan.gossai@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Nathan Gossai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Cole, MD</last_name>
      <phone>718-741-2356</phone>
      <email>peter.cole@einstein.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria-Luisa Sulis, MD</last_name>
      <phone>212-305-5808</phone>
      <email>Mls95@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Maria-Luisa Sulis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Tasian, MD</last_name>
      <phone>267-425-0118</phone>
      <email>TasianS@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Tasian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Cooper, MD</last_name>
      <phone>206-987-1533</phone>
      <email>Todd.Cooper@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Todd Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Burke, MD</last_name>
      <email>mmburke@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Yana Pikman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Recurrent, Refractory, or High Risk Leukemias</keyword>
  <keyword>Matched targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

